Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 595084
                    [Title] => Roche submits US FDA application for 'T-DM1'
                    [Summary] => 
Roche announced recently that it submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for trastuzumab-DM1 (T-DM1) in people with advanced HER2-positive breast cancer who have previously received multiple HER2-targeted medicines and chemotherapies.
                    [DatePublished] => 2010-07-22 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 56417
                    [Title] => GSK gets favorable FDA recommendation
                    [Summary] => 
            
                    [DatePublished] => 2008-04-17 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

BIOLOGICS LICENSE APPLICATION

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 595084
                    [Title] => Roche submits US FDA application for 'T-DM1'
                    [Summary] => 
Roche announced recently that it submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for trastuzumab-DM1 (T-DM1) in people with advanced HER2-positive breast cancer who have previously received multiple HER2-targeted medicines and chemotherapies.
                    [DatePublished] => 2010-07-22 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 56417
                    [Title] => GSK gets favorable FDA recommendation
                    [Summary] => 
            
                    [DatePublished] => 2008-04-17 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Roche submits US FDA application for 'T-DM1'

July 22, 2010 - 12:00am

Roche announced recently that it submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for trastuzumab-DM1 (T-DM1) in people with advanced HER2-positive breast cancer who have...

Science and Environment

GSK gets favorable FDA recommendation

April 17, 2008 - 12:00am

Science and Environment